Ambulatory and self-monitoring of blood pressure: Coming of age Peter W. de Leeuw Invited Commentary Pages: 173 - 175
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes Jay GargGeorge L. Bakris OriginalPaper Pages: 185 - 190
The use of calcium antagonists in the treatment of hypertensive persons with kidney disease Sheldon TobeMurray Epstein OriginalPaper Pages: 191 - 194
Carcinogenicity of antihypertensive therapy Ehud GrossmanFranz H. MesserliUri Goldbourt OriginalPaper Pages: 195 - 201
Effects of antihypertensive therapy on sexual activity in hypertensive men Roberto FogariAnnalisa Zoppi OriginalPaper Pages: 202 - 210
Antihypertensive drugs and cognitive function Anne-Sophie RigaudM. G. M. Olde-RikkertFrançoise Forette OriginalPaper Pages: 211 - 215
Resistant hypertension David A. CalhounMohammad A. ZamanMari K. Nishizaka OriginalPaper Pages: 221 - 228
Sympathetic nervous system function in renal hypertension Meryem TuncelRobert AugustyniakRonald G. Victor OriginalPaper Pages: 229 - 236
Dopamine receptor-coupling defect in hypertension Pedro A. JoseGilbert M. EisnerRobin A. Felder OriginalPaper Pages: 237 - 244
Functional tests for primary aldosteronism: Value of captopril suppression Marie-Claude RacinePierre DouvilleMarcel Lebel OriginalPaper Pages: 245 - 249
Choice of biochemical test for diagnosis of pheochromocytoma: Validation of plasma metanephrines Graeme EisenhoferJacques W. M. LendersKarel Pacak OriginalPaper Pages: 250 - 255